WASHINGTON (AP) - The Latest on the House Oversight and Government Reform hearing on rising EpiPen prices (all times local):
3:30 p.m.
The head of pharmaceutical company Mylan is defending the cost for life-saving EpiPens, signaling the company has no plans to lower prices despite a public outcry and questions from skeptical lawmakers.
In testimony for Congress, CEO Heather Bresch says she believes Mylan has struck a balance between price and access to the drug. The price of EpiPens has grown to $608 for a two-pack, an increase of more than 500 percent since 2007.
Bresch says the company does not want to go back to a time when awareness of allergic reactions was much lower and many schools did not stock the drug.
The House Oversight and Government Reform Committee is questioning Bresch about the pricing.